Supernus Pharmaceuticals, Inc. (SUPN) Social Stream



Supernus Pharmaceuticals, Inc. (SUPN): $27.48

0.37 (+1.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Supernus Pharmaceuticals Inc (SUPN) Price Targets From Analysts

Use the tables below to see what analysts covering Supernus Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-28 3 $37 $30 $34 $32.18 5.66%
2022-01-25 4 $44 $30 $36.5 $32.18 13.42%
2022-03-02 4 $44 $30 $36 $32.18 11.87%

The Trend in the Analyst Price Target


SUPN's average price target has moved up $8.67 over the prior 21 months.

SUPN reports an average of 22.7% for its upside potential over the past 46 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-05 4 40 30 35.0 29.88 17.14%
2021-07-17 4 40 30 35.0 26.45 32.33%
2021-09-18 4 40 30 35.0 27.28 28.3%
2021-11-03 3 37 30 34.0 30.03 13.22%
2022-01-13 4 44 30 36.5 29.20 25%

SUPN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.5 3 0 1 0 0 4

The Trend in the Broker Recommendations


SUPN's average broker recommendation rating improved by 0.5 over the prior 19 months.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SUPN as an investment opportunity.

  • In the context of all US stocks, Supernus Pharmaceuticals Inc's number of analysts covering the stock is higher than 68.38% of them.
  • In terms of how Supernus Pharmaceuticals Inc fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 24.27% of that group.
  • SUPN has a lower variance in analysts' estimates than 6.48% of Pharmaceutical Products stocks.
  • SUPN has a higher average analyst price target than 166.27% of stocks in the mid market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Supernus Pharmaceuticals Inc are STTK, STOK, and SPPI.

Make investment decisions regarding SUPN using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4002 seconds.